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Volume 3Available online 26 May 2020Background: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP
chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This
phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense
R-CODOX-M/R-IVAC regimen.
Patients and methods: Eligible patients were aged 18e65 years with stage IIeIV untreated DLBCL and an International
Prognostic Index (IPI) score of 3e5. Patients received alternating cycles of CODOX-M (cyclophosphamide, vincristine,
doxorubicin and high-dose methotrexate) alternating with IVAC chemotherapy (ifosfamide, etoposide and high-dose
cytarabine) plus eight doses of rituximab. Response was assessed by computed tomography after completing all
four cycles of chemotherapy. The primary end point was 2-year progression-free survival (PFS).
Results: A total of 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4/5
(39.6%), 54% had a performance status 2 and 9% had central nervous system involvement. A total of 85 patients
(76.6%) completed all four cycles of chemotherapy. There were five treatment-related deaths (4.3%), all in patients
with performance status of 3 and aged >50 years. Two-year PFS for the whole cohort was 67.9% [90% confidence
interval (CI) 59.9e74.6] and 2-year overall survival was 76.0% (90% CI 68.5e82.0). The ability to tolerate and
complete treatment was lower in patients with performance status 2 who were aged >50 years, where 2-year
PFS was 43.5% (90% CI 27.9e58.0).
Conclusions: This trial demonstrates that R-CODOX-M/R-IVAC is a feasible and effective regimen for the treatment of
younger and/or fit patients with high-risk DLBCL. These encouraging survival rates demonstrate that this regimen
warrants further investigation against standard of care.
Trial Registration: ClinicalTrials.gov (NCT00974792) and EudraCT (2005-003479-19).
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1 - Issue 9 - 2020INTRODUCTION
The addition of rituximab to standard CHOP chemotherapy
[cyclophosphamide, doxorubicin, vincristine and predniso-
lone (R-CHOP)] has improved survival rates for diffuse large
B-cell lymphoma (DLBCL) and other forms of high-grade B-
cell lymphoma (HGBL) by 10%e15%.1e3 However, a third of
DLBCL patients still progress after R-CHOP, and outcomes
for these patients are extremely poor.4e6 The greatest un-
met need is for patients with high-risk disease; R-CHOP
failure rates for patients with an International Prognostic
Index (IPI) score of 3e5 approach 50%.7e10https://doi.org/10.1016/j.annonc.2020.05.016 1251
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to improve on standard 21-day R-CHOP chemotherapy for
untreated DLBCL. Increasing the dose density of R-CHOP has
not been shown to improve outcomes,11 nor has consoli-
dation with high-dose therapy-autologous stem cell trans-
plantation.12e14 Randomised studies have not shown clear
evidence of benefit for incorporation of novel agents for
most patients.15e19 Several attempts to incorporate addi-
tional chemotherapeutic agents have similarly failed to
improve outcomes.20,21
There is some evidence, however, that treatment inten-
sification can improve survival. The phase 3 GELA LNH03-2B
trial demonstrated an overall survival (OS) advantage for
treatment with R-ACVBP (rituximab, doxorubicin, cyclo-
phosphamide, vindesine, bleomycin and prednisolone) plus
consolidation chemotherapy over R-CHOP in patients with
an age-adjusted IPI score (aaIPI) of 1, albeit with unex-
pectedly poor outcomes in the R-CHOP arm.22 Favourable
outcomes have been achieved with the same regimen for
high-risk patients (aaIPI 2e3), although it remains unclear
whether there is a benefit over R-CHOP in this group.23,24 A
number of population-based and non-randomised studies
have suggested that combining etoposide with R-CHOP can
improve outcomes for high-risk patients, although rando-
mised studies in the rituximab era are lacking.25,26
A different approach is widely used in Burkitt lymphoma
(BL), using rapid cycling of dose-dense chemotherapy,
combining hyperfractionated alkylating agents with multi-
ple central nervous system (CNS)epenetrating agents.27
One such example is the Magrath regimen, consisting of
alternating cycles of CODOX-M (cyclophosphamide,
vincristine, doxorubicin and high-dose methotrexate) and
IVAC chemotherapy (ifosfamide, etoposide and cytar-
abine),28 which, with the addition of rituximab, can achieve
survival rates in BL approaching 80%, even in patients with
multiple high-risk features.29,30 The LY10 study demon-
strated that the same treatment regimen, without ritux-
imab, was both feasible and effective in highly proliferative
DLBCL and HGBL.28 Two-year OS was 59% with CODOX-M/
IVAC in patients with a proliferation rate >95%. The aim
of this UK National Cancer Research Institute (NCRI) trial
was to build on these encouraging results and assess the
efficacy of CODOX-M and IVAC, together with rituximab, for
the treatment of high-risk DLBCL.
METHODS
This trial was designed as two parallel single-arm trials to
treat both DLBCL and BL patients with the same regimen
under the same protocol, with crossover between arms
according to central pathology review. Outcomes for DLBCL
patients are reported here; outcomes for BL patients will be
reported separately.Eligibility
Patients were eligible for this phase 2 trial if aged 18e65
years with stage IIeIV newly diagnosed DLBCL (or any
morphological variant according to World Health1252 https://doi.org/10.1016/j.annonc.2020.05.016Organisation (WHO) Classification of Lymphoid Neo-
plasms)31,32 and an IPI score of 3. Prior corticosteroid
treatment was permitted but no other chemotherapy or
radiotherapy. Performance status (PS) was permissive, but
patients must have been deemed able to tolerate the
intensive regimen with adequate renal, liver and cardiac
function. A protocol amendment allowed inclusion of HIV-
positive patients with PS 2 and baseline CD4 count
100 cells/mm3, with no history of opportunistic infection.
Diagnostic tissue was centrally reviewed by the Leeds
Haematological Malignancy Diagnostic Service, UK. Cell of
origin was assessed post hoc according to the Hans algo-
rithm.33 FISH studies for MYC, BCL2 and BCL6 translocations
were not mandated but were routinely performed in pa-
tients recruited in later stages of the trial. Disease staging
was with contrast-enhanced computed tomography (CT) of
the neck to pelvis, bone marrow biopsy and cerebrospinal
fluid examination. All patients provided informed consent
prior to study entry.
Study treatment and assessments
Patients received two cycles of CODOX-M alternating with
two cycles of IVAC, plus eight doses of rituximab (375 mg/
m2; Table 1). Subsequent treatment cycles were
commenced as soon as neutrophils were >1  109/l and
platelets >75  109/l. Tumour lysis prophylaxis with allo-
purinol or rasburicase was commenced prior to study
treatment. All patients received supportive care with
pegylated granulocyteecolony stimulating factor, aciclovir
and Pneumocystis jirovecii prophylaxis.
Response was assessed by contrast-enhanced CT ac-
cording to standard criteria,34 1 month after completion of
chemotherapy. Use of positron emission tomography (PET)
was encouraged but was not routinely available in the UK at
the time of study design. Radiotherapy consolidation was
permitted at investigators’ discretion to initial sites of dis-
ease bulk, intraparenchymal CNS disease and sites of re-
sidual positron emission tomography-positive disease.
Adverse events were assessed according to the Common
Terminology Criteria for Adverse Events version 3.0.
End points and statistical methods
The primary end point was progression-free survival (PFS) at
2 years. Secondary end points included complete response
(CR) rate and toxicity. At the time of study design, PFS for
DLBCL patients with IPI 3e5 after standard therapy was
estimated to be 40%e50%, based on historical data and
assuming a 10%e15% improvement in the rituximab era. A
PFS rate of 65% was deemed to warrant further investi-
gation but a rate of 45% would be of no interest. Using a
Fleming design, it was calculated that a sample size ofw95
patients would have 90% power to detect a 15% difference
at 5% (one-sided) significance. The trial was designed to
treat both BL and DLBCL patients under one protocol and
was terminated once the total target sample size of 150
patients was met, irrespective of numbers of DLBCL pa-
tients recruited. PFS was calculated as the time fromVolume 31 - Issue 9 - 2020
Table 1. R-CODOX-M and R-IVAC regimen
R-CODOX-M regimen IVAC regimen
Rituximab 375 mg/m2 i.v. Days 1 and 11 Rituximab 375 mg/m2 i.v. Day 1
Cyclophosphamide 800 mg/m2 i.v.
200 mg/m2 i.v.
Day 1
Day 2-5
Etoposide 60 mg/m2 Days 1e5
Vincristine 1.5 mg/m2 i.v. (max 2 mg) Days 1 and 8 Ifosfamide 1500 mg/m2 Days 1e5
Doxorubicin 40 mg/m2 i.v. Day 1 Mesna 1200 mg Days 1e5
Cytarabine 70 mg i.t. Days 2 and 4
Day 6b if CNS disease
Cytarabine 2000 mg/m2 i.v. 12 h Days 1 and 2
Methotrexate 3000 mg/m2 i.v. over 24 hd Day 10 Methotrexate 12 mg i.t. Day 5
Leucovorin From 36 h after methotrexate until clearance, starting at
a dose of 15 mg/m2 i.v. 6 h
Pegfilgrastim 6 mg s.c. Day 7
Pegfilgrastim 6 mg s.c. Day 13 Cytarabine 70 mg i.t. Days 7 and 9, if CNS diseaseb
Methotrexate 12 mg i.t. Day 15
Day 17b if CNS disease
Rituximabc 375 mg/m2 i.v. Days 21 and 42
CNS, central nervous system; CODOX-M, cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate; i.t., intrathecal; i.v., intravenous; IVAC, ifosfamide, etoposide and
high-dose cytarabine; R-CODOX-M, rituximab þ R-CODOX-M; R-IVAC, rituximab þ IVAC; s.c., subcutaneous.
a Estimated timeline based on median cycle length.
b First cycle of R-CODOX-M and R-IVAC only, for patients with evidence of CNS disease.
c After fourth cycle of chemotherapy (second IVAC cycle) only.
d 300 mg administered over 1 h followed by 2700 mg over 23 h.
A. K. McMillan et al. Annals of Oncologyregistration until progression or death. Patients who were
alive and progression-free were censored at the date last
seen. Competing risks survival analysis was used to calcu-
late the risk of CNS relapse, with death and systemic-only
relapse treated as competing events. All analyses were
performed using Stata version 15.1 (StataCorp, College
Station, TX).RESULTS
Patient characteristics
Between May 2008 and April 2013, 121 patients were
registered with DLBCL at 32 UK centres. Three patients were
deemed ineligible prior to treatment and have been
excluded from all analyses (Figure 1). An additional seven
patients were found not to meet eligibility criteria after
starting treatment and have been included in toxicity ana-
lyses only. One eligible patient did not commence treat-
ment because of rapid disease progression and was
included in survival, but not toxicity, analyses.
The primary analysis included 111 DLBCL patients.
Baseline clinical and pathological characteristics are shown
in Table 2. Central pathology review was performed in 86
patients (77.5%); pathology reports issued by haematopa-
thologists were reviewed for all other patients to confirmVolume 31 - Issue 9 - 2020DLBCL. FISH studies were performed equally in germinal
centre (GC) B-cell and non-GC DLBCL; seven patients (12.3%
of those assessed) had double-hit cytogenetics.
Study treatment
Eighty-five patients (77.3%) completed all four cycles of
chemotherapy. The median interval between the start of
consecutive treatment cycles was 27 days between cycles 1
and 2 (range 18e45), 23 days between cycles 2 and 3
(range 16e53) and 30 days between cycles 3 and 4 (range
21e83). The interval was 35 days for 16.5% (44/266) of
treatment cycles.
Twenty-five patients (22.7%) stopped treatment early,
after receiving one (n ¼ 16), two (n ¼ 3) or three (n ¼ 6)
cycles of chemotherapy. The main reason for early
discontinuation was toxicity (n ¼ 18; Figure 1). Patients
were less likely to complete chemotherapy if aged 50
years (62.5%, compared with 92.7% <50 years; P < 0.001),
or if PS ¼ 3 (54.6%, compared with 83.2% for PS 0e2; P ¼
0.004).
Radiotherapy consolidation was given to 13 of 85 (15.3%)
patients. Only one of 20 (5%) patients with baseline tumour
bulk 7.5 cm was irradiated after achieving CR. Two pa-
tients received allogeneic stem cell transplant off-trial in CR,
one of whom died of transplant-related complications.https://doi.org/10.1016/j.annonc.2020.05.016 1253
DLBCL patients registered
N = 121
Excluded prior to study treatment
N = 3
Hepatitis 
IPI score <3
Not fit for treatment
Safety analysis population
(toxicity)
N = 117
Started treatment
N = 110
Did not start treatment
N = 1
Rapid progression
Primary analysis population
N = 111
Excluded (found to be ineligible
after treatment)
N = 7
Prior spinal RT n = 1
n = 1 n = 1
n = 1
n = 1
n = 1
n = 3
n = 1
n = 1
Hepatitis 
IPI score <3
MCL
Concurrent 
T-cell lymphoma
Given all 4 cycles
N = 85
Did not complete treatment
Toxicity
Death – TRM 
Death – Lymphoma
Patient refusal
Other medical condition
Lack of understanding
Clinician decision (deviation)
N = 25
n = 15
n = 3
n = 2
n = 2
n = 1
n = 1
n = 1
Figure 1. Consort diagram.
DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; MCL, mantle cell lymphoma; RT, radiotherapy; TRM, treatment-related mortality.
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Grade 3e5 adverse events are detailed in Table 3. As ex-
pected, haematological toxicity was high with this dose-
intense regimen, with 88% grade 4 neutropoenia and
61.1% grade 4 thrombocytopoenia. Grade 3 non-
haematological toxicity occurred in 88.9%, the most
frequent of which were infections (70.9%), mucositis
(31.6%) and febrile neutropoenia (17.9%). Intracranial
haemorrhage occurred in six patients (5.1%), all during the
first cycle and in patients without CNS disease. One patient
(0.9%) developed secondary acute myeloid leukaemia. One
patient who had received prior radiotherapy for spinal
lymphoma (thus should have been ineligible, although it
was only reported after completing study treatment)
developed paraparesis secondary to radiotherapy-induced
spinal necrosis, emphasising the need for caution with
intensive CNS-directed therapy after CNS irradiation.
Treatment-related mortality (TRM) was 4.3%, with five
deaths, due to neutropoenic sepsis (n ¼ 3) and haemor-
rhage (n ¼ 2; intracranial and gastrointestinal). These pa-
tients were all aged >50 years with a PS of 3 at registration.Outcomes
For eligible patients that commenced R-CODOX-M (N ¼
110), overall response rate by CT was 74.5%: 52 patients
(47.3%) achieved CR/unconfirmed CR (CRu) and 30 (27.3%)
achieved partial response (PR). Seven patients (8.2%) had
stable or progressive disease and 20 patients (18.2%) did
not undergo response assessment because of early treat-
ment termination or death (Figure 1).
With a median follow-up of 54.6 months for the whole
cohort (N ¼ 111), 30 patients have relapsed or died of
lymphoma and eight died without progression (38 PFS1254 https://doi.org/10.1016/j.annonc.2020.05.016events). The 2- and 4-year PFS rates were 67.9% [90%
confidence interval (CI) 59.9e74.6] and 66.9% (90% CI
58.9e73.7), respectively (Figure 2A). The 2- and 4-year OS
rates were 76.0% (90% CI 68.5e82.0) and 72.8% (90% CI
64.9e79.2), respectively (Figure 2B). There have been 32
deaths in total, due to lymphoma (n ¼ 22), TRM (n ¼ 5),
toxicity of further treatment (n ¼ 3), pneumonia (n ¼ 1)
and other malignancy (T-cell lymphoma; n ¼ 1).
A post hoc analysis assessing the effect of age and PS
highlighted worse outcomes for patients with PS 2 who
were aged>50 years (Figure 2C), which was largely driven by
excess TRM in this group (supplementary Table S1, available
atAnnals of Oncology online).Therewas no clear difference in
outcomes for thosewith IPI score 3 comparedwith thosewith
IPI score 4 or 5 (supplementary Figure S1A, available at Annals
of Oncology online). There was also no overt difference in
outcomes for DLBCL diagnoses made by external versus
central pathology review, or between patients with a GCB-cell
phenotype and non-GC disease (supplementary Figure S1B
and C, available at Annals of Oncology online), albeit ac-
cording to the Hans algorithm, which is an imperfect predictor
of cell of origin. Although numbers are small, outcomes for
patients with double-hit lymphomawere not overtly different
from other DLBCL patients in whom FISH excluded double-hit
disease (supplementary Figure 1D, available at Annals of
Oncology online).
Central nervous system-directed therapy. For patients with
CNS involvement at registration (n ¼ 10), 2-year PFS was
70% (32.9%e89.2%), without any patient receiving radio-
therapy or high-dose therapy and stem cell transplant in CR.
There was one isolated CNS progression; the other two
patients had either refractory disease or concurrent sys-
temic progression.Volume 31 - Issue 9 - 2020
Table 2. Baseline characteristics
Baseline characteristic N [ 111
Demographics
Age (years), median (range) 50 (18e65)
Sex, n (%)
Female 45 (40.5)
Male 66 (59.5)
Prognostic factors, n (%)
Age
60 98 (88.3)
>60 13 (11.7)
WHO performance status
0 23 (20.7)
1 28 (25.2)
2 38 (34.2)
3 22 (19.8)
Stage
III 7 (6.3)
IV 104 (93.7)
More than 1 extra nodal site
No 23 (20.7)
Yes 88 (79.3)
LDH above upper limit of normal
No 5 (4.5)
Yes 106 (95.5)
IPI score, n (%)
3 67 (60.4)
4 43 (38.7)
5 1 (0.9)
Other baseline demographics, n (%)
Age-adjusted IPI score
1 1 (0.9)
2 54 (48.6)
3 56 (50.5)
B symptoms
Absent 34 (30.6)
Present 77 (69.4)
CNS disease at registration
Yes 10 (9.0)
No 101 (91.0)
HIV status
Negative 108 (99.1)
Positive 1 (0.9)
Unknown 2
Disease bulk 10 cm
Present 38 (39.6)
Absent 58 (60.4)
Incomplete information 15
LDH 3 ULN, n (%)
No 60 (56.1)
Yes 47 (43.9)
Unknown 4
Pathology classification (post hoc review), n (%)
Cell of origin
GCB 54 (54.0)
Non-GCB 46 (46.0)
Unknown 11
Double-hit
No 50 (87.7)
Yes 7 (12.3)
Unknown 54
CNS, central nervous system; GCB, germinal centre B-cell; HIV, human immunode-
ficiency virus; IPI, International Prognostic Index; LDH, lactate dehydrogenase; ULN,
upper limit of normal; WHO, World Health Organisation.
A. K. McMillan et al. Annals of OncologyFor patients without evidence of CNS involvement (N ¼
101), CNS relapse risk according to the CNS-IPI35 was
evaluable for 90 (89.1%; supplementary Table S2, available
at Annals of Oncology online). There were no CNS relapses
in intermediate-risk patients (n ¼ 38). There were two CNSVolume 31 - Issue 9 - 2020relapses among 58 high-risk patients, both without evi-
dence of systemic disease, giving a 2-year CNS relapse rate
of 3.6% (95% CI 0.9e13.8).
Outcomes for relapsed/refractory disease. Twenty-six pa-
tients experienced disease progression after R-CODOX-M/R-
IVAC, nine of whom relapsed from CR/CRu, and two pa-
tients received further treatment for inadequate response
(PR and stable disease). Of these, 20 patients (71.4%)
received intensive salvage chemotherapy, five (17.9%) were
palliated and further treatment history is unknown in three
(10.7%). Seven patients with relapsed/refractory disease
(25.0%) are alive, with a minimum of 29 months’ follow-up
post-progression.
DISCUSSION
This trial demonstrates that treatment with R-CODOX-M/R-
IVAC is both feasible and effective in a high-risk group of
DLBCL/HGBL patients. The primary end point was met, with
a 2-year PFS rate of 67.9% (90% CI 59.9e74.6), exceeding
the 65% target and comfortably excluding the lower limit of
45%.
Our results appear to compare favourably with contem-
porary outcomes with R-CHOP in high-risk DLBCL, notwith-
standing the inherent limitations of making comparisons
between studies.We report a 4-year PFS rate of 66.9% (90%CI
58.9e73.7), despite inclusion of patients with CNS involve-
ment, in whom R-CHOP is ineffective, and patients with PS
>2, who are excluded from many prospective trials.11 In the
UK NCRI R-CHOP 14-21 trial,11 5-year PFS for high-risk DLBCL
patients (IPI 3e5), aged60 years with PS 0e2 was 54.4%.10
In other large cohorts of patients treated with R-CHOP or
similar regimens, PFS rates at 4e5 years for patients with IPI
score 3 and 4 or 5 were 54%e59% and 41%e56%, respec-
tively.8,9 Outcomes in this trial were similar to those reported
with other intensive treatment regimens.24,25 We observed a
4-year OS rate of 72.8%, compared with 78% for high-risk
patients (aaIPI 2e3) treated with the R-ACVBP regimen,
noting that CNS disease was excluded in the latter and fewer
patients (58%) had IPI score 3e5.24
The main limitation of this trial is the lack of a rando-
mised comparator, particularly in light of the failure of other
apparently promising regimens to translate into a survival
benefit over R-CHOP in phase 3 trials.16,17,19,21 Our findings
must therefore be interpreted with caution and randomised
studies are clearly required if this regimen is to be brought
forwards into standard care for high-risk DLBCL. However,
conducting a large phase 3 trial in this relatively small
subset of DLBCL patients with widespread disease and poor
PS, many of whom require urgent chemotherapy, will be
challenging.
Toxicity with R-CODOX-M/R-IVAC was greater than ex-
pected with R-CHOP, particularly with respect to haemato-
logical toxicity, infection and mucositis, but was manageable
for most patients. TRM was 4.3%, which is comparable to
TRM rates with other intensive treatment strategies12,22,24
but higher than the 1%e2% TRM seen in most R-CHOP tri-
als.11,21 All treatment-related deaths occurred in patientshttps://doi.org/10.1016/j.annonc.2020.05.016 1255
Table 3. Grade 3e5 adverse events
CTCAE system organ class/event Worst grade
Grade 3e4 Grade 5
N ¼ 117
n (%) n (%)
Blood and bone marrow 115 (98.3)
Anaemia 32 (27.4)
Leukopenia 14 (12.0)
Neutropaenia 112 (95.7)
Thrombocytopaenia 110 (94.0)
Cardiac 12 (10.3)
Cardiac NOS 10 (8.5)
Hypotension 2 (1.7)
Constitutional 26 (22.2)
Fatigue 7 (6.0)
Fever 20 (17.1)
Dermatology and skin: rash 2 (1.7)
Gastrointestinal 56 (47.9)
Anorexia 12 (10.3)
Diarrhoea 10 (8.5)
Mucositis 37 (31.6)
Nausea 14 (12.0)
Perforated small bowel 2 (1.7)
Vomiting 7 (6.0)
Haemorrhage 9 (7.7) 2 (1.7)
CNS 5 (4.3) 1 (0.1)
Gastrointestinal 4 (3.4) 1 (0.1)
Infection 80 (68.4) 3 (2.6)
Febrile neutropoenia 21 (17.9)
Infection 72 (61.5) 3 (2.6)
Sepsis 3 (2.6)
Laboratory/Metabolism 20 (17.1)
Hypokalaemia 7 (6.0)
Abnormal transaminases or bilirubin 8 (6.8)
Neurology 16 (13.7)
Mood alterations 2 (1.7)
Neurological NOS 11 (9.4)
Pain 18 (15.4)
Gastrointestinal 3 (2.6)
Musculoskeletal 5 (4.3)
Headache 7 (6.0)
Pain NOS 4 (3.4)
Chest 3 (2.6)
Pulmonary/Upper respiratory 11 (9.4)
Dyspnoea 4 (3.4)
Pleural effusion 3 (2.6)
Syndromes 3 (2.6)
Tumour lysis 2 (1.7)
Vascular 3 (2.6)
DVT/thrombosis 3 (2.6)
Non-haematological 99 (84.6) 5 (4.3)
Any CTCAE grades 3D 112 (95.7) 5 (4.4)
Data listed by organ class according to the Common Toxicity Criteria for Adverse
Events version 3. Individual grade 3 events are only listed if occurring in 2 pa-
tients.
CNS, central nervous system; CTCAE, Common Toxicity Criteria for Adverse Events
(version 3.0); DVT, deep vein thrombosis; NOS, not otherwise specified.
Annals of Oncology A. K. McMillan et al.aged >50 years with PS 3. These deaths and higher rates of
early treatment discontinuation highlight the need for
caution in using this regimen for older patients (>50 years)
with PS 2. A corticosteroid prephase may improve PS and
allow for better assessment of suitability for intensive
treatment. Use of published dose-adjusted CODOX-M/IVAC
protocols for older/less-fit patients may also improve toler-
ability,28,36 although alternative regimens may be warranted1256 https://doi.org/10.1016/j.annonc.2020.05.016for such patients. The resource burden with R-CODOX-M/R-
IVAC is higher than with R-CHOP, usually requiring inpatient
administration, but the duration of treatment (14 weeks) is
shorter than with R-CHOP-21 (18 weeks) and other intensive
regimens, such as R-ACVBP (26 weeks).22
One benefit of R-CODOX-M/R-IVAC is the ability to
deliver multiple CNS-directed agents, particularly to those
with concurrent CNS involvement or at highest risk of CNS
relapse. The favourable outcomes for those with CNS
involvement in this trial demonstrate the feasibility of this
approach for secondary CNS lymphoma, although patient
numbers are small, and our findings require exploration in
larger cohorts. It is also noteworthy that none of these
patients received high-dose therapy and stem cell trans-
plant or radiotherapy consolidation in CR. There were also
fewer CNS relapses than anticipated in this trial, with
observed 2-year CNS progression rates of 0% and 3.6% for
patients with intermediate- and high-risk CNS IPI scores,
respectively, compared with 3.4%e3.9% and 10.2%e12.0%,
respectively, in R-CHOP-treated patients.35
R-CODOX-M/R-IVAC has already been used to treat spe-
cific high-risk groups of HGBL, particularly those with
‘double-hit’ lymphoma, based on retrospective evidence of
efficacy.37,38 Only 51.4% of patients underwent FISH studies
in this trial, which was conceived prior to the widespread
use of FISH to identify double-hit patients. Therefore, our
findings cannot be extrapolated to recently categorised
HGBL populations in the 2016 WHO Classification of
Lymphoid Neoplasms.39 Where FISH studies were per-
formed, the frequency of double-hit cytogenetics in our
high-risk DLBCL cohort (12%) was not appreciably higher
than the reported incidence in wider DLBCL cohorts (5%e
10%). There was no clear difference in outcomes for the few
patients with double-hit lymphoma in this trial. This dem-
onstrates that adverse risk is multifactorial and double-hit
lymphoma accounts for only a small proportion of ‘high-
risk’ HGBL. Our findings suggest that R-CODOX-M/R-IVAC
may have broader applicability across high-risk patients
with both HGBL and DLBCL.
One argument against the use of intensive upfront
treatment is the limited availability of treatment options in
the event of relapse; R-IVAC contains several agents that
are typically used in salvage regimens. However, outcomes
after DLBCL progression are generally poor, with PFS rates
following intensive salvage therapy of only 20%e30% across
studies.4e6 Even with chimeric antigen receptor T-cell
therapy, relatively short-term PFS rates for the selected
patients included in pivotal trials remain below 40% on a
per-protocol basis, and intention-to-treat analyses are
lacking.40,41 In this trial, 25% of all patients with relapsed/
refractory disease are alive and in ongoing remission, in
keeping with other studies and emphasising the importance
of effective front-line treatment.
In summary, this phase 2 trial demonstrates that R-
CODOX-M/R-IVAC is an effective regimen for the treatment
of high-risk DLBCL, with promising survival rates. Toxicity
with this intensive regimen was manageable for mostVolume 31 - Issue 9 - 2020
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Figure 2. KaplaneMeier curves for (A) progression-free survival and (B) overall survival. (C) Progression-free survival according to age and performance status (PS).
A. K. McMillan et al. Annals of Oncologypatients, although it was less well tolerated in patients aged
>50 years with impaired PS (2). Our findings indicate that
R-CODOX-M/R-IVAC warrants being explored further in
comparative studies against standard R-CHOP
chemotherapy.Volume 31 - Issue 9 - 2020ACKNOWLEDGEMENTS
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